Straits Times Index
3,304.72 +11.79 (+0.36%) Nikkei
38,236.07 -38.03 (-0.10%) Hang Seng
18,505.61 +29.69 (+0.16%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,780.25 +513.37 (+0.81%) CMC Crypto 200
1,328.78 +51.80 (+4.06%)
CHRS May 2024 2.000 call
| Previous close | 0.2700 |
| Open | 0.3500 |
| Bid | 0.0500 |
| Ask | 0.4500 |
| Strike | 2.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.3500 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 2.34k |
GlobeNewswireCoherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion o
- GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114
Simply Wall St.Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
